Yahoo Finance reported on July 4, 2026, that the State Street SPDR Health Care Select Sector ETF XLH has surpassed the Invesco Pharmaceutical ETF PJP on two key competitive metrics. XLH now manages over $7.2 billion more in assets than its rival. The fund also maintains a lower expense ratio, solidifying its position as a dominant vehicle for institutional investors seeking broad healthcare exposure.
Context — why this matters now
The shift comes as ETF providers intensify their focus on cost efficiency in the healthcare sector. Fee compression has been a persistent trend since the late 2010s, but the pace accelerated after Vanguard Group's major fee cuts across its sector ETF lineup in late 2023. The average expense ratio for a U.S. healthcare sector ETF has fallen from 0.13% in 2020 to 0.10% in 2026.
The current macro backdrop features elevated interest rates, with the 10-year Treasury yield stabilizing near 4.2%. This environment places a premium on investment efficiency, making a fund's expense ratio a more critical selection factor for investors seeking to maximize net returns.
The primary catalyst for XLH's asset dominance is a multi-year rotation by large pension funds and asset managers. These institutions are consolidating allocations into a single, large, and liquid healthcare sector ETF to simplify portfolio management and reduce trading costs.
Data — what the numbers show
As of early July 2026, the State Street Health Care ETF XLH holds approximately $16.4 billion in assets under management. The Invesco Pharmaceutical ETF PJP manages roughly $9.2 billion. This $7.2 billion gap represents the largest-ever asset differential between these two competing funds.
XLH charges a net expense ratio of 0.09%. The Invesco Pharmaceutical ETF PJP carries a higher expense ratio of 0.20%. This 11 basis point difference translates to $1.10 in annual fees per $1,000 invested, a meaningful cost drag for large portfolios.
| Metric | State Street XLH | Invesco PJP |
|---|
| AUM | $16.4 billion | $9.2 billion |
| Expense Ratio | 0.09% | 0.20% |
| YTD Return* | +4.6% | +2.1% |
*Returns through July 3, 2026. XLH's portfolio, with holdings like Eli Lilly (LLY) and UnitedHealth (UNH), has outperformed PJP's concentrated pharmaceutical basket, which includes Pfizer (PFE) and AbbVie (ABBV). The broader S&P 500 is up 3.8% year-to-date.
Analysis — what it means for markets / sectors / tickers
The asset consolidation into XLH directly benefits the top holdings within its index. The fund's index is market-cap weighted, meaning giants like Eli Lilly and UnitedHealth receive the largest inflows from new fund investments. This creates a self-reinforcing cycle where liquidity begets more assets. Conversely, stocks that are exclusive to the PJP portfolio, such as some smaller-cap pharmaceutical names, miss out on this passive flow.
The primary counter-argument is that PJP offers a focused, pure-play pharmaceutical strategy that may appeal to investors seeking targeted exposure, justifying its higher fee. Its equal-weight methodology also provides diversification benefits not captured by a market-cap-weighted fund like XLH, which is heavily concentrated in its top ten holdings.
Positioning data from the past quarter shows consistent net inflows into XLH exceeding $450 million, while PJP has seen minor outflows of around $30 million. The flow is clearly moving toward the lower-cost, larger-scale fund, a pattern mirroring the broader ETF market where scale and cost are the primary drivers of allocation.
Outlook — what to watch next
Key catalysts for these ETF flows include the next round of earnings reports from major healthcare constituents, starting with UnitedHealth Group on July 18, 2026. Earnings performance for pharmaceutical heavyweights like Eli Lilly on August 1 will also influence sector sentiment and subsequent ETF demand.
Investors will monitor the 0.20% expense ratio level for PJP. A failure to attract new assets may pressure Invesco to enact a fee cut to remain competitive. For XLH, watch for whether its asset base can sustainably cross the $17 billion threshold, a level that would further cement its liquidity advantage.
The primary risk is a sharp rotation out of the defensive healthcare sector should the Federal Reserve signal a more aggressive rate-cutting cycle at its September FOMC meeting. Such a scenario could trigger outflows from all healthcare ETFs, testing the resilience of their respective investor bases.
Frequently Asked Questions
What is the difference between XLH and PJP?
The State Street Health Care ETF XLH tracks the Health Care Select Sector Index, providing exposure to the entire U.S. healthcare sector, including managed care, equipment, and services. The Invesco Pharmaceutical ETF PJP tracks an equal-weighted index of only U.S. pharmaceutical companies. XLH is market-cap weighted and holds about 65 stocks, while PJP holds around 25. This makes XLH a broader, diversified healthcare bet, while PJP is a concentrated pharmaceutical industry play.
How does expense ratio size affect long-term ETF returns?
A higher expense ratio directly reduces an investor's net return. For example, on a $10 million investment, the 0.11% fee difference between XLH and PJP amounts to $11,000 in annual costs. Compounded over ten years in a flat market, this fee drag would result in the PJP investor's portfolio being worth approximately $115,000 less than an identical investment in XLH, purely due to costs.
Does this trend impact actively managed healthcare funds?
Yes. The dominance of large, low-cost ETFs like XLH puts significant fee pressure on actively managed mutual funds in the healthcare space. These funds must justify their higher fees, often above 0.70%, by consistently outperforming the benchmark index. The availability of a 0.09% ETF alternative raises the bar for active managers, likely accelerating the shift of assets from active funds to passive ETFs within the sector.
Bottom Line
Scale and cost are now decisive advantages in the healthcare ETF arena, with State Street's XLH consolidating institutional capital at the expense of pricier, more niche competitors.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
